https://www.ema.europa.eu/en/homepageOrphan designationsen-gbCopyright: (C) European Medicines AgencyWed, 17 Jul 2024 12:33:48 +0200Fri, 28 Jun 2024 12:00:00 +0200https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2369Orphan designation: sotatercept Treatment of pulmonary arterial hypertension, 09/12/2020 Positivehttps://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2369Fri, 28 Jun 2024 12:00:00 +0200Orphan designationshttps://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2656Orphan designation: Odronextamab Treatment of diffuse large B-cell lymphoma, 18/07/2022 Positivehttps://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2656Fri, 28 Jun 2024 12:00:00 +0200Orphan designationshttps://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2649Orphan designation: Odronextamab Treatment of follicular lymphoma, 18/07/2022 Positivehttps://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2649Fri, 28 Jun 2024 12:00:00 +0200Orphan designationshttps://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-596Orphan designation: monoclonal antibody against human CD30 covalently linked to the cytotoxin monomethylauristatin E (brentuximab vedotin) Treatment of Hodgkin's lymphoma, 15/01/2009 Withdrawnhttps://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-596Wed, 26 Jun 2024 17:30:00 +0200Orphan designationshttps://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-939Orphan designation: Brentuximab vedotin Treatment of cutaneous T-cell lymphoma, 11/01/2012 Withdrawnhttps://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-939Wed, 26 Jun 2024 17:30:00 +0200Orphan designations